Debora Russo

Debora Russo

Auto-generated profile, based on publicly available information

Debora Russo

D3 Pharmachemistry, Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genova, Italy

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2016 in Journal of Materials Chemistry B
Verified
Journal Article
Open access
PDF file
HHHadi Hajiali
Hadi Hajiali
MSMaria Summa
Maria Summa
DRDebora Russo
Debora Russo
Andrea ArmirottiAndrea Armirotti
Andrea Armirotti
VBVirgilio Brunetti
Virgilio Brunetti
Elisa MeleElisa Mele
Elisa Mele
One of the current challenges in wound care is the development of multifunctional dressings that can both protect the wound from external agents and promote the regeneration of the new tissue. Here, we show the combined use of two naturally derived compounds, sodium alginate and lavender essential oil, for the production of bioactive nanofibrous dressings by electrospinning, and their efficacy for the treatment of skin burns induced by midrange ultraviolet radiation (UVB). We demonstrate that the engineered dressings reduce the risk of microbial infection of the burn, since they stop the growth of Staphylococcus aureus. Furthermore, they are able to control and reduce the inflammatory response that is induced in human foreskin fibroblasts by lipopolysaccharides, and in rodents by UVB exposure. In particular, we report a remarkable reduction of pro-inflammatory cytokines when fibroblasts or animals are treated with the alginate-based nanofibers. The down-regulation of cytokines production and the absence of erythema on the skin of the treated animals confirm that the here described dressings are promising as advanced biomedical devices for burn management.

1 January 2018 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
MSMaria Summa
Maria Summa
DRDebora Russo
Debora Russo
IPIlaria Penna
Ilaria Penna
NMNatasha Margaroli
Natasha Margaroli
Ilker BayerIlker Bayer
Ilker Bayer
Rosalia BertorelliRosalia Bertorelli
Rosalia Bertorelli

15 March 2011 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
PMPaola Monti
Paola Monti
CPChiara Perfumo
Chiara Perfumo
ABAlessandra BISIO
Alessandra BISIO
Yari CiribilliYari Ciribilli
Yari Ciribilli
PMPaola Menichini
Paola Menichini
GFGilberto Fronza
Gilberto Fronza
Germline TP53 mutations result in cancer proneness syndromes known as Li-Fraumeni, Li-Fraumeni-like, and nonsyndromic predisposition with or without family history. To explore genotype/phenotype associations, we previously adopted a functional classification of all germline TP53 mutant alleles based on transactivation. Severe deficiency (SD) alleles were associated with more severe cancer proneness syndromes, and a larger number of tumors, compared with partial deficiency (PD) alleles. Because mutant p53 can exert dominant-negative (DN) effects, we addressed the relationship between DN and clinical manifestations. We reasoned that DN effects might be stronger in familial cancer cases associated with germline TP53 mutations, where mutant alleles coexist with the wild-type allele since conception. We examined 104 p53 mutant alleles with single amino acid substitutions described in the IARC germline database for (i) transactivation capability and (ii) capacity to reduce the activity of the wild-type allele (i.e., DN effect) using a quantitative yeast-based assay. The functional classifications of p53 alleles were then related to clinical variables. We confirmed that a classification based on transactivation alone can identify familial cancer cases with more severe clinical features. Classification based on DN effects allowed us to highlight similar associations but did not reveal distinct clinical subclasses of SD alleles, except for a correlation with tumor tissue prevalence. We conclude that in carriers of germline TP53 mutations transactivation-based classification of TP53 alleles appears more important for genotype/phenotype correlations than DN effects and that haplo-insufficiency of the TP53 gene is an important factor in cancer proneness in humans. Mol Cancer Res; 9(3); 271–9. ©2011 AACR.

1 July 2018 in Carbohydrate Polymers
Verified
Journal Article
Closed access
José Alejandro Heredia-GuerreroJosé Alejandro Heredia-Guerrero
José Alejandro Heredia-Guerrero
LCLuca Ceseracciu
Luca Ceseracciu
Susana Guzman-PuyolSusana Guzman-Puyol
Susana Guzman-Puyol
UPUttam Paul
Uttam Paul
AAAlejandro Alfaro-Pulido
Alejandro Alfaro-Pulido
Ilker BayerIlker Bayer
Ilker Bayer

12 July 2016 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
PDF file
MMMarco Migliore
Marco Migliore
SPSilvia Pontis
Silvia Pontis
AAAngel Luis Fuentes de Arriba
Angel Luis Fuentes de Arriba
NRNatalia Realini
Natalia Realini
ETEsther Torrente
Esther Torrente
DPDaniele Piomelli
Daniele Piomelli
Palmitoylethanolamide (PEA) and oleoylethanolamide (OEA) are endogenous lipid mediators that suppress inflammation. Their actions are terminated by the intracellular cysteine amidase, N‐acylethanolamine acid amidase (NAAA). Even though NAAA may offer a new target for anti‐inflammatory therapy, the lipid‐like structures and reactive warheads of current NAAA inhibitors limit the use of these agents as oral drugs. A series of novel benzothiazole–piperazine derivatives that inhibit NAAA in a potent and selective manner by a non‐covalent mechanism are described. A prototype member of this class (8) displays high oral bioavailability, access to the central nervous system (CNS), and strong activity in a mouse model of multiple sclerosis (MS). This compound exemplifies a second generation of non‐covalent NAAA inhibitors that may be useful in the treatment of MS and other chronic CNS disorders.

1 November 2017 in Algal Research
Verified
Journal Article
Closed access
Susana Guzman-PuyolSusana Guzman-Puyol
Susana Guzman-Puyol
DRDebora Russo
Debora Russo
IPIlaria Penna
Ilaria Penna
LCLuca Ceseracciu
Luca Ceseracciu
FPFrancisco Palazon
Francisco Palazon
AAAthanassia Athanassiou
Athanassia Athanassiou